Lawyers for GlaxoSmithKline were enjoying something of a winning streak in their efforts to remove drug products liability lawsuits to federal court — and keep them there — by arguing that it has converted to a limited liability company that is based in Delaware.

But that streak may now be over.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]